Neurocrine biosciences exercises option to license idorsia's treatment for pediatric epilepsy

Neurocrine biosciences inc - exercises option to license idorsia's novel treatment for rare pediatric epilepsy.neurocrine biosciences - to develop, commercialize act-709478, clinical stage selective t-type calcium channel blocker for rare pediatric epilepsy.neurocrine biosciences inc - idorsia receives a $45 million upfront payment in cash.neurocrine biosciences - idorsia will be entitled to potential development, regulatory milestone payments up to $365 million,tiered royalties on net sales.
NBIX Ratings Summary
NBIX Quant Ranking